• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Nonalcoholic Steatohepatitis (NASH)
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for NASH trials.

DOWNLOAD BROCHURE

Effective solutions for advancing NASH research

Nonalcoholic steatohepatitis (NASH), a type of fatty liver disease due to causes other than alcohol, characterized by inflammation of the liver that may progress to fibrosis and cirrhosis if not adequately treated. With the disease's prevalence expected to increase by 63% by 2030, there's a pressing need to develop effective, new treatments. NASH studies face challenges, including poor retention rates and patients who suffer from comorbidities. Signant SmartSignals solutions and team of experts provide the support needed to generate high-quality evidence.

Why Signant Health

  • Collect Accurate Data
  • Assess Cognitive Functions
  • Keep Patients Engaged
  • Track Sleep & Activity
  • Alleviate Patient Concerns
  • Offer Remote Capabilities
  • Collect Accurate Data

    Collect Accurate Data

    Signant SmartSignals eCOA contains disease-specific questionnaires that assess the effect of treatment on quality of life and various functions. Its digital format eliminates the need to transcribe from paper and provides time-stamped, original, and attributable data.
     

  • Assess Cognitive Functions

    Assess Cognitive Functions

    Our Cognitive Assessments is a fit-for-purpose tool that detects subtle changes in mental capabilities to understand the treatment’s effect on cognitive functions. The validated and highly sensitive disease agnostic tool precisely measures essential cognitive domains, including attention, information processing, executive function, as well as episodic and working memory.
     
     

  • Keep Patients Engaged

    Keep Patients Engaged

    Conveniently located on the same app as our eCOA solution, the patient engagement solution promotes ongoing communication between sites and clinical trial patient. The engagement tool sends study updates and alerts for upcoming visits.

     
     
     

  • Track Sleep & Activity

    Track Sleep & Activity

    Integrating Actigraph sensors and wearables with our Signant SmartSignals eCOA can provide valuable insights into the impact of the disease and treatment beyond liver fibrosis. The objective, real-time sleep and activity measures offer a better understanding of the overall impact of the disease and treatment on a patient’s quality of life.
     
     

  • Alleviate Patient Concerns

    Alleviate Patient Concerns

    The Signant SmartSignals eConsent solution uses engaging multimedia to educate potential participants on study requirements including biopsies. Designed to support various learning styles, the digital tool enables patients to flag sections they need further clarification on and checks their comprehension for a truly informed consent.
     
     
     

  • Offer Remote Capabilities

    Offer Remote Capabilities

    Signant SmartSignals Telemedicine recreates the clinic experience in a virtual platform and can replace the visits that do not require in person appointments such as blood tests, scans, or biopsies. Study teams will have an easier and more efficient way to check in on NASH patients after adverse events have occurred.

Comprehensive NASH experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our NASH trial resources
SOLUTION BROCHURE

NASH Trial Solutions Overview


GET INSIGHTS
VIDEO

NASH Trial Solutions



WATCH [2 MIN]
BROCHURE

Immunology Clinical Trial Solutions

 
READ BROCHURE

eClinical solutions for NASH trials

Accelerate your NASH trial success

Discover how Signant's specialized solutions can address unique challenges in your current or upcoming NASH research.

DISCUSS PROTOCOL